Serum NfL as an MS biomarker

A large real-world study has evaluated the use of serum neurofilament light chain (sNfL) as a biomarker for multiple sclerosis (MS). Levels of this protein were measured in 6,974 people with MS and 201 healthy individuals using a high-throughput immunoassay. sNfL was elevated in a significant proportion of people with MS. The levels correlated with severity of physical and cognitive disability, brain atrophy and radiological inflammatory disease activity, validating sNfL as a useful biomarker for MS.

留言 (0)

沒有登入
gif